CannaLnx in the Spotlight

Every April 20, the high holiday for marijuana lovers, is a reason to examine the state of the $30 billion cannabis industry. And this year, there is tremendous optimism that federal reform is finally coming.

For decades, cannabis lived in the margins of healthcare, whispered about in waiting rooms and quietly relied on by patients long before anyone in a lab coat said it was okay. Now, as legalization spreads and stigma softens, the question isn’t just whether people use cannabis: it’s whether the systems built to manage our health are ready to acknowledge it.

The cannabis industry continues to grow, but not without some problematic flash points in the first half of 2026. For starters, the global cannabis industry is expected to reach $102.7 billion in 2026 and $428.2 billion by 2032, according to Fortune Business Insights, while support for legalizing cannabis stands at 87%.

After a quiet period, cannabis M&A activity is back. Following President Donald Trump’s December executive order directing cannabis rescheduling, marijuana multistate operators are acquiring distressed assets and expanding footprints across mature markets. Consolidation is framed as a sign of renewed confidence.

Momentum around federal cannabis reform has shifted. Following President Donald Trump’s executive order directing the rescheduling of cannabis, investors have interpreted the move as a meaningful step toward normalization. Multistate operators are accelerating acquisitions. Capital markets are cautiously reengaging. Optimism is back in the headlines.

A Cleveland-based health technology company says it has developed a system that could significantly change how patients pay for medical marijuana in states where it is legal.

A Cleveland-based health technology company says it has developed a system that could significantly change how patients pay for medical marijuana in states where it is legal.

Interviews Matthew Myro Rothman, Chief Science Officer, CannaLnx – Interview Seriesmm Published January 22, 2026 By Josh Kasoff Matthew Myro Rothman, Chief Science Officer, CannaLnx – Interview Series As more states legalize medicinal cannabis and existing markets continue to mature, there is a growing need for a centralized hub that connects patients with care providers and dispensaries. Beyond just access, patients also require an intuitive way to identify the specific products that will best serve their needs. Fortunately, that solution has arrived. To discuss this technology and how it empowers medical cannabis patients, mycannabis.com spoke with Matthew Myro Rothman, Chief Science Officer of CannaLnx.

The CannaLnx Platform is a HIPAA-compliant digital solution that claims to digitize the recommendation and certification process as well as the medical-cannabis supply chain. The company provides validation for medical cannabis purchases at network dispensaries to be able to receive reimbursement for those purchases.

The American Council of Cannabis Medicine has been quietly working behind the scenes to prepare for a future where cannabis is recognized as legitimate medicine—and reimbursable through health insurance.

A Cleveland-based health-tech company, EM2P2, has launched a platform that could change how Americans pay for medical cannabis. Its new product, CannaLnx, claims to make cannabis care reimbursable, compliant, and accessible by finally allowing patients to apply health-benefit dollars toward cannabis purchases in legal states.

After arriving in town, our first stop was lunch with Head Magazine Associate Editor Corey Benjamin who had arrived from Chicago, at the iconic Peppermill Restaurant and Fireside Lounge, a Las Vegas landmark. The Peppermill delivers exactly what you want at the start of a busy conference week: wild retro décor, famously generous portions, and the glow of its beloved firepit. The perfect warm-up.

The moment many in the cannabis industry have been waiting for has finally arrived. Operators, investors, and advocates are cautiously celebrating President Trump’s executive order directing the Department of Justice to finalize the rescheduling of cannabis to Schedule III, an action many hope is a stepping stone toward full federal descheduling.

Trump has signed an executive order to speed up cannabis rescheduling, potentially easing tax burdens for companies and boosting investment. However, industry experts say challenges remain.

Activists Bash Trump’s Call to Renew Drug WarLegalTrump Weighs Executive Order to Advance Cannabis Rescheduling ByCannabis NowPublished on December 12, 2025 ShareTweet President Donald Trump is weighing an executive order that would push the federal government to reclassify cannabis, a step that could mark the most significant shift in U.S. cannabis policy in decades—even as the White House cautions that no final decision has been made.

According to a report published on December 11, 2025, by The Washington Post, President Donald Trump is considering an executive order that would direct federal agencies to reclassify marijuana from Schedule I to Schedule III under the Controlled Substances Act. This potential shift, which could occur as early as Monday, December 15, would represent a significant federal policy adjustment, easing certain restrictions while maintaining prohibitions on non-medical use. However, a White House official stated that no final decisions have been made, according to Forbes.

A new US spending bill will recriminalize most hemp-derived THC products by late 2026, threatening the hemp industry's growth and jobs.

Medical cannabis has become a fixture in the healthcare conversation, with millions of Americans using it to manage chronic pain, epilepsy, PTSD, and a range of other conditions. Yet, despite expanding legalization and widespread patient demand, the question of insurance coverage remains largely unanswered. For now, most patients are left paying out of pocket — a financial burden that can be especially heavy for those who rely on cannabis as a daily treatment.

Medical marijuana patients may soon be able to get reimbursed for doctors’ visits, cannabis products and MMJ cards.

Healthcare coverage for cannabis treatments remains elusive in the United States, but a new reimbursement initiative may offer limited relief for medical marijuana (MMJ) patients in some states.

Medical cannabis has become a fixture in the healthcare conversation, with millions of Americans using it to manage chronic pain, epilepsy, PTSD, and a range of other conditions. Yet, despite expanding legalization and widespread patient demand, the question of insurance coverage remains largely unanswered. For now, most patients are left paying out of pocket — a financial burden that can be especially heavy for those who rely on cannabis as a daily treatment.